Lupus
Impressive data on novel treatment for SLE were presented at the EULAR22 Congress. A disease that is difficult to study due to its pleomorphic presentation, unpredictable disease course, and high mortality rates, SLE is considered the dragon of all autoimmune diseases. Here are highlights of four exciting abstracts presented at the meeting with emerging therapeutics designed to slay the beast.
Bags are packed, ready to go, but wait there’s more abstracts to show.
The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest of study data often is showcased.
Here are my favorite late-breakers from Day 4.
Robert B Chao, MD doctorRBC
3 years 4 months ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-controlled study
Met primary endpoint SRI response across all doses
No death, MACE, VTE, systemic infections
@RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
Richard Conway RichardPAConway
3 years 4 months ago
Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9
Richard Conway RichardPAConway
3 years 5 months ago
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 5 months ago
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
Eric Dein ericdeinmd
3 years 5 months ago
#EULAR2022 LB0005
Orelabrutinib- BTKi- for SLE, PIb/IIa
⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4
⭐️Improved proteinuria
@Rheumnow https://t.co/bmREhmL7sq
TheDaoIndex KDAO2011
3 years 5 months ago
Another possible Rx for #SLE:
Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvement in SRI-4, SLEDAI2K, proteinuria, dsDNA, C3/C4; dec in IgG/M/Bcells. Safety: lymphopenia w/ORE #EULAR2022 LB0005 @rheumnow https://t.co/etZ9hMYNfn
Aurelie Najm AurelieRheumo
3 years 5 months ago
Orelabrutinib Bruton’s
tyrosine kinase inhibitor in SLE
RCT phase Ib/IIa
SRI(4) wk 12 50mg 50% 80mg 61% and 100mg 64% and 37.5% PBO
Trend ⬇️ proteinuria, anti-dsDNA & IgG
Safety: 3SAEs in OLE group
LB0005 @RheumNow #EULAR2022 https://t.co/4r16NTaZvT
David Liew drdavidliew
3 years 5 months ago
@EricFMorand up first in late-breakings
PAISLEY: deucravacitinib (TYK2i) ph2 in SLE - add-on, steroid wean
Good outcomes:
primary: SRI(4) at 32w
skin/joint/LLDAS & dsDNA/C4
Safety good (like PsO/PsA) but higher dose less so
Watch for: other clinical, ph3
#EULAR2022 @RheumNow https://t.co/XOQWuiHkTx
TheDaoIndex KDAO2011
3 years 5 months ago
Wow! Phase 2 #deucravacitinib data for #SLE met primary & secondary endpoints: SRI(4) response, BICLA, LLDAS, CLASI-50. AEs include: skin related events and UTIs but no increase in SIE, HZ, MACE/VTE @bmsnews LB0004 #EULAR022 @rheumnow https://t.co/bsKI0mixVT
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 5 months ago
#POS1236 #EULAR2022 More data to justify safety of #COVID vaccination to our #lupus patients. A study in Italy (>450 pts) found 1/4 had side effects (mostly mild) and 4% had a flare. These side effects were more common in those on >1 DMARDS and Belimumab @RheumNow https://t.co/mNS6rQfsSq
Poster Hall